Results for toxicity translation from Finnish to Swedish

toxicity
toxicity

developmental toxicity testing
developmental toxicity testing

repeat- dose (90 days) toxicity testing
repeat- dose (90 days) toxicity testing

revised note for guidance on repeated dose toxicity
revised note for guidance on repeated dose toxicity

adjunctive treatment in patients at risk of methotrexate toxicity
adjunctive treatment in patients at risk of methotrexate toxicity

sctee, scientific committee on toxicity, ecotoxicity and the environment.
vetenskapliga kommittén för toxicitet, ekotoxicitet och miljö.

toxicity discussion paper on possible pre- clinical studies to investigate addiction and
toxicity discussion paper on possible pre- clinical studies to investigate addiction and

asiakirjan nimi points to consider on the need for assessment of reproductive toxicity of human insulin analogues
dokumenttitel points to consider on the need for assessment of reproductive toxicity of human insulin analogues

duration of chronic toxicity testing in animals (rodent and non- rodent toxicity testing)
duration of chronic toxicity testing in animals (rodent and non- rodent toxicity testing)

qtc- ajan piteneminen ei ylittänyt vaikeusastetta 2 (common toxicity criteria v3. 0) yhdelläkään tutkimushenkilöllä.
5 förlängning av qtc- intervallet som var större än grad 2 (ctcae version 3).

muistio immunotoxicity and the need to update the notes for guidance on repeat dose toxicity and on non - clinical local tolerance testing of medicinal products
underlag för riktlinjer immunotoxicity and the need to update the notes for guidance on repeat dose toxicity and on non - clinical local tolerance testing of medicinal products

näissä taulukoissa toksisuuden luokittelu perustuu national cancer institute common toxicity criteria (nci- ctc): n kriteereihin.
graderingen av toxiciteten i dessa tabeller baseras på "national cancer institute common toxicity criteria" (nci- ctc).

kliinisissä kokeissa ilmeni hoitoon liittyviä ctc (common toxicity criteria) - luokan 3 ja 4 haittavaikutuksia 37 prosentilla potilaista.
besläktade biverkningar av ctc, grad 3 och 4 inträffade hos 37% av patienterna i kliniska studier.

usetox – the unep-setac toxicity model: recommended characterisation factors for human toxicity and freshwater ecotoxicity in life cycle impact assessment.
”usetox - the unep-setac toxicity model: recommended characterisation factors for human toxicity and freshwater ecotoxicity in life cycle impact assessment”.

[8] public health and economic consequences of methyl mercury toxicity to the developing brain, environmental health perspectives 113, may 2005.--------------------------------------------------
[8] public health and economic consequences of methyl mercury toxicity to the developing brain, environmental health perspectives 113, maj 2005.

pre- approval information for registration of new medicinal products for food producing animals with respect to antimicrobial resistance injection site residues user safety estimation of predicted environmental concentrations, including harmonisation of default values and development of a harmonised computer model toxicity of substances to dung fauna degradation of substances in manure
pre- approval information for registration of new medicinal products for food producing animals with respect to antimicrobial resistance injection site residues user safety estimation of predicted environmental concentrations, including harmonisation of default values and development of a harmonised computer model toxicity of substances to dung fauna degradation of substances in manure

niiden esiintymistiheys perustuu vain vakaviin tapauksiin (≥3 aste ncinn (national cancer institute) common toxicity criteria - luokituksen mukaisesti).
för varje biverkning baserades den beräknade frekvensen på alla grader av reaktioner (från mild till allvarlig), förutom för biverkningar markerade med "+" där frekvensen endast baserades på allvarliga (≥ grad 3 nci common toxicity criteria) reaktioner.

24 taulukossa 2 on nci- ctc- kriteerien (national cancer institute- common toxicity criteria) mukainen tiivistelmä keskeisessä pa. 3- tutkimuksessa esiintyneistä haittavaikutuksista, jotka olivat yleisempiä (≥ 3%) tarcevaa 100 mg: n annoksina ja gemsitabiinia saaneilla potilailla kuin plaseboa ja gemsitabiinia saaneessa ryhmässä, ja joita esiintyi vähintään 10%: lla tarcevaa 100 mg ja gemsitabiinia saaneista potilaista.
biverkningar som uppträdde mer frekvent (≥ 3%) hos de patienter som behandlades med tarceva 100 mg plus gemcitabin jämfört med den grupp som fick placebo plus gemcitabin i den pivotala studien pa. 3, och hos minst 10% av patienterna i gruppen som fick tarceva 100 mg plus gemcitabin, sammanfattas med gradering enligt national cancer institute- common toxicity criteria (nci- ctc) i tabell 2.